CMS-Run Medicaid Purchasing Pools For High-Cost Drugs Floated In Budget
Executive Summary
Administration’s proposal to increase Medicaid leverage via more “unified” approach adds another idea to drug-pricing debates, though it would require legislation.
You may also be interested in...
Have You Heard The Latest Rumor On Drug Pricing? Orrin Hatch Has
An exchange during HHS Secretary Burwell’s testimony to the Finance Committee on the fiscal 2017 budget speaks volumes about what is – and is not – on the table for the last year of the Obama Administration.
CMS Wants To Facilitate Value-Based Discounts For HCV Drugs In Medicaid
CMS requests information from hepatitis C manufacturers on how value-based purchasing arrangements might work in Medicaid. Agency also urges state Medicaid directors to relax overly strict coverage requirements for the drugs.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.